Regulatory milestones

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) gained $0.19 (16%) to $1.38 on Monday after receiving a preliminary comment letter from FDA that the company said "outlines a pathway" by which the biotech could submit an NDA for IV peramivir to treat influenza. BioCryst declined to disclose details.